Biotinylated Human CD20 Full Length Protein (VLP)
Produktgrößen
20 ug
£1555,00
CD0-H82P3-20UG
100 ug
£2508,00
CD0-H82P3-100UG
500 ug
£7265,00
CD0-H82P3-500UG
Über dieses Produkt
- SKU:
- CD0-H82P3
- Buffer:
- PBS, Arginine, pH7.4
- Konjugat:
- Biotin
- Weitere Details:
- B-lymphocyte antigen CD20 is also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1, is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. CD20 is expressed on all stages of B cell development except the first and last; it is present from late pro-B cells through memory cells, but not on either early pro-B cells or plasma blasts and plasma cells. It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. The protein has no known natural ligand and its function is to enable optimal B-cell immune response, specifically against T-independent antigens. It is suspected that it acts as a calcium channel in the cell membrane. CD20 / MS4A1 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5); also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.
- Immunogen:
- CD20
- Physischer Zustand:
- Liquid
- Versandbedingungen:
- Dry Ice
- Lagerbedingungen:
- -70[o]C
- Hersteller:
- ACRO Biosystems
- Typ:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Recombinant Proteins
